Cystic fibrosis pulmonary guidelines: Airway clearance therapies

Patrick A. Flume, Karen A. Robinson, Brian P. O'Sullivan, Jonathan Finder, Robert L. Vender, Donna Beth Willey-Courand, Terry B. White, Bruce C. Marshall, Janet Bujan, Anne Downs, Jonathan Finder, Chris Goss, Leslie Hazle, Mary Lester, Bruce Marshall, Peter Mogayzel, Lynne Quittell, Randall Rosenblatt, Kathryn Sabadosa

Research output: Contribution to journalReview article

158 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is a genetic disease characterized by dehydration of airway surface liquid and impaired mucociliary clearance. As a result, there is difficulty clearing pathogens from the lung, and patients experience chronic pulmonary infections and inflammation. Clearance of airway secretions has been a primary therapy for those with CF, and a variety of airway clearance therapies (ACTs) have been developed. Because ACTs are intrusive and require considerable time and effort, it is important that appropriate techniques are recommended on the basis of available evidence of efficacy and safety. Therefore, the Cystic Fibrosis Foundation established a committee to examine the clinical evidence for each therapy and provide guidance for their use. A systematic review was commissioned, which identified 7 unique reviews and 13 additional controlled trials that addressed one or more of the comparisons of interest and were deemed eligible for inclusion. Recommendations for use of the ACTs were made, balancing the quality of evidence and the potential harms and benefits. The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the evidence quality overall for their use in CF is fair and the benefit is moderate. The committee recommends airway clearance be performed on a regular basis in all patients. There are no ACTs demonstrated to be superior to others, so the prescription of ACTs should be individualized. Aerobic exercise is recommended as an adjunctive therapy for airway clearance and for its additional benefits to overall health.

Original languageEnglish (US)
Pages (from-to)522-537
Number of pages16
JournalRespiratory care
Volume54
Issue number4
StatePublished - Apr 1 2009

Fingerprint

Cystic Fibrosis
Guidelines
Therapeutics
Mucociliary Clearance
Inborn Genetic Diseases
Dehydration
Prescriptions
Pneumonia
Exercise
Safety
Lung
Health
Infection

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Flume, P. A., Robinson, K. A., O'Sullivan, B. P., Finder, J., Vender, R. L., Willey-Courand, D. B., ... Sabadosa, K. (2009). Cystic fibrosis pulmonary guidelines: Airway clearance therapies. Respiratory care, 54(4), 522-537.

Cystic fibrosis pulmonary guidelines : Airway clearance therapies. / Flume, Patrick A.; Robinson, Karen A.; O'Sullivan, Brian P.; Finder, Jonathan; Vender, Robert L.; Willey-Courand, Donna Beth; White, Terry B.; Marshall, Bruce C.; Bujan, Janet; Downs, Anne; Finder, Jonathan; Goss, Chris; Hazle, Leslie; Lester, Mary; Marshall, Bruce; Mogayzel, Peter; Quittell, Lynne; Rosenblatt, Randall; Sabadosa, Kathryn.

In: Respiratory care, Vol. 54, No. 4, 01.04.2009, p. 522-537.

Research output: Contribution to journalReview article

Flume, PA, Robinson, KA, O'Sullivan, BP, Finder, J, Vender, RL, Willey-Courand, DB, White, TB, Marshall, BC, Bujan, J, Downs, A, Finder, J, Goss, C, Hazle, L, Lester, M, Marshall, B, Mogayzel, P, Quittell, L, Rosenblatt, R & Sabadosa, K 2009, 'Cystic fibrosis pulmonary guidelines: Airway clearance therapies', Respiratory care, vol. 54, no. 4, pp. 522-537.
Flume PA, Robinson KA, O'Sullivan BP, Finder J, Vender RL, Willey-Courand DB et al. Cystic fibrosis pulmonary guidelines: Airway clearance therapies. Respiratory care. 2009 Apr 1;54(4):522-537.
Flume, Patrick A. ; Robinson, Karen A. ; O'Sullivan, Brian P. ; Finder, Jonathan ; Vender, Robert L. ; Willey-Courand, Donna Beth ; White, Terry B. ; Marshall, Bruce C. ; Bujan, Janet ; Downs, Anne ; Finder, Jonathan ; Goss, Chris ; Hazle, Leslie ; Lester, Mary ; Marshall, Bruce ; Mogayzel, Peter ; Quittell, Lynne ; Rosenblatt, Randall ; Sabadosa, Kathryn. / Cystic fibrosis pulmonary guidelines : Airway clearance therapies. In: Respiratory care. 2009 ; Vol. 54, No. 4. pp. 522-537.
@article{7d1cce8130674f7bb40a31b64bbe65c5,
title = "Cystic fibrosis pulmonary guidelines: Airway clearance therapies",
abstract = "Cystic fibrosis (CF) is a genetic disease characterized by dehydration of airway surface liquid and impaired mucociliary clearance. As a result, there is difficulty clearing pathogens from the lung, and patients experience chronic pulmonary infections and inflammation. Clearance of airway secretions has been a primary therapy for those with CF, and a variety of airway clearance therapies (ACTs) have been developed. Because ACTs are intrusive and require considerable time and effort, it is important that appropriate techniques are recommended on the basis of available evidence of efficacy and safety. Therefore, the Cystic Fibrosis Foundation established a committee to examine the clinical evidence for each therapy and provide guidance for their use. A systematic review was commissioned, which identified 7 unique reviews and 13 additional controlled trials that addressed one or more of the comparisons of interest and were deemed eligible for inclusion. Recommendations for use of the ACTs were made, balancing the quality of evidence and the potential harms and benefits. The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the evidence quality overall for their use in CF is fair and the benefit is moderate. The committee recommends airway clearance be performed on a regular basis in all patients. There are no ACTs demonstrated to be superior to others, so the prescription of ACTs should be individualized. Aerobic exercise is recommended as an adjunctive therapy for airway clearance and for its additional benefits to overall health.",
author = "Flume, {Patrick A.} and Robinson, {Karen A.} and O'Sullivan, {Brian P.} and Jonathan Finder and Vender, {Robert L.} and Willey-Courand, {Donna Beth} and White, {Terry B.} and Marshall, {Bruce C.} and Janet Bujan and Anne Downs and Jonathan Finder and Chris Goss and Leslie Hazle and Mary Lester and Bruce Marshall and Peter Mogayzel and Lynne Quittell and Randall Rosenblatt and Kathryn Sabadosa",
year = "2009",
month = "4",
day = "1",
language = "English (US)",
volume = "54",
pages = "522--537",
journal = "Respiratory Care",
issn = "0020-1324",
publisher = "Daedalus Enterprises Inc.",
number = "4",

}

TY - JOUR

T1 - Cystic fibrosis pulmonary guidelines

T2 - Airway clearance therapies

AU - Flume, Patrick A.

AU - Robinson, Karen A.

AU - O'Sullivan, Brian P.

AU - Finder, Jonathan

AU - Vender, Robert L.

AU - Willey-Courand, Donna Beth

AU - White, Terry B.

AU - Marshall, Bruce C.

AU - Bujan, Janet

AU - Downs, Anne

AU - Finder, Jonathan

AU - Goss, Chris

AU - Hazle, Leslie

AU - Lester, Mary

AU - Marshall, Bruce

AU - Mogayzel, Peter

AU - Quittell, Lynne

AU - Rosenblatt, Randall

AU - Sabadosa, Kathryn

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Cystic fibrosis (CF) is a genetic disease characterized by dehydration of airway surface liquid and impaired mucociliary clearance. As a result, there is difficulty clearing pathogens from the lung, and patients experience chronic pulmonary infections and inflammation. Clearance of airway secretions has been a primary therapy for those with CF, and a variety of airway clearance therapies (ACTs) have been developed. Because ACTs are intrusive and require considerable time and effort, it is important that appropriate techniques are recommended on the basis of available evidence of efficacy and safety. Therefore, the Cystic Fibrosis Foundation established a committee to examine the clinical evidence for each therapy and provide guidance for their use. A systematic review was commissioned, which identified 7 unique reviews and 13 additional controlled trials that addressed one or more of the comparisons of interest and were deemed eligible for inclusion. Recommendations for use of the ACTs were made, balancing the quality of evidence and the potential harms and benefits. The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the evidence quality overall for their use in CF is fair and the benefit is moderate. The committee recommends airway clearance be performed on a regular basis in all patients. There are no ACTs demonstrated to be superior to others, so the prescription of ACTs should be individualized. Aerobic exercise is recommended as an adjunctive therapy for airway clearance and for its additional benefits to overall health.

AB - Cystic fibrosis (CF) is a genetic disease characterized by dehydration of airway surface liquid and impaired mucociliary clearance. As a result, there is difficulty clearing pathogens from the lung, and patients experience chronic pulmonary infections and inflammation. Clearance of airway secretions has been a primary therapy for those with CF, and a variety of airway clearance therapies (ACTs) have been developed. Because ACTs are intrusive and require considerable time and effort, it is important that appropriate techniques are recommended on the basis of available evidence of efficacy and safety. Therefore, the Cystic Fibrosis Foundation established a committee to examine the clinical evidence for each therapy and provide guidance for their use. A systematic review was commissioned, which identified 7 unique reviews and 13 additional controlled trials that addressed one or more of the comparisons of interest and were deemed eligible for inclusion. Recommendations for use of the ACTs were made, balancing the quality of evidence and the potential harms and benefits. The committee determined that, although there is a paucity of controlled trials that assess the long-term effects of ACTs, the evidence quality overall for their use in CF is fair and the benefit is moderate. The committee recommends airway clearance be performed on a regular basis in all patients. There are no ACTs demonstrated to be superior to others, so the prescription of ACTs should be individualized. Aerobic exercise is recommended as an adjunctive therapy for airway clearance and for its additional benefits to overall health.

UR - http://www.scopus.com/inward/record.url?scp=66849124547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66849124547&partnerID=8YFLogxK

M3 - Review article

C2 - 19327189

AN - SCOPUS:66849124547

VL - 54

SP - 522

EP - 537

JO - Respiratory Care

JF - Respiratory Care

SN - 0020-1324

IS - 4

ER -